Ovarian Cancer | Specialty

Adopting Neoadjuvant Therapy into Ovarian Cancer

April 26th 2018

Niraparib Active in Heavily Pretreated Ovarian Cancer, Regardless of BRCA Status

April 24th 2018

Niraparib (Zejula) met the primary endpoint of overall response as a fourth-line or later treatment in patients with ovarian cancer, regardless of BRCA status, according to top-line results from the QUADRA study.

Dr. Wingo on the Evolution of Surgery in Patients With Ovarian Cancer

April 23rd 2018

Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses surgical options for the treatment of patients with newly-diagnosed ovarian cancer.

Dr. Monk on Combination Therapies in Patients With Ovarian Cancer

April 20th 2018

Bradley J. Monk, MD, professor and director, Division of Gynecologic Oncology, Creighton University School of Medicine, Arizona Oncology, discusses combination approaches in patients with ovarian cancer.

Dr. Janicek on Genetic Testing in Patients With Ovarian Cancer

April 18th 2018

Mike Janicek, MD, medical director, Division of Genetics, Arizona Oncology, discusses the use of genetic testing in patients with ovarian cancer.

Streamlined, Oncologist-Led BRCA Testing Viable in Ovarian Cancer

April 18th 2018

An oncologist-led BRCA mutation testing pathway in the ENGAGE study has led researchers to conclude that pretest counseling by the oncology team could shorten testing turnaround times and ease the pressure on genetic counselors.

Dr. Willmott on Mechanisms of Resistance in Ovarian Cancer

April 16th 2018

Lyndsay J. Willmott, MD, gynecologic oncologist, Arizona Oncology, discusses the mechanisms of resistance to PARP inhibitors that have been identified in ovarian cancer.

Dr. Scribner on the Role of Chemotherapy in Ovarian Cancer

April 13th 2018

Dennis R. Scribner, MD, FACOG, FACS, clinical associate professor for the University of Arizona School of Medicine, Arizona Oncology, discusses the use of chemotherapy in patients with ovarian cancer.

Dr. Janicek Discusses Progress in Genetic Testing for Ovarian Cancer

April 10th 2018

Mike Janicek, MD, medical director, Genetics Division, Arizona Oncology, discusses progress with genetic testing in ovarian cancer.

Dr. Dalton on the Standard of Care in Ovarian Cancer

April 10th 2018

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses the standard of care for patients with ovarian cancer.

Dr. Monk on the FDA Approval of Maintenance Rucaparib in Ovarian Cancer

April 7th 2018

Bradley J. Monk, MD, FACOG, FACS, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Arizona Oncology, discusses the FDA approval of rucaparib (Rubraca) as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Dr. O'Malley on FDA Approval of Maintenance Rucaparib in Ovarian Cancer

April 6th 2018

David O'Malley, MD, gynecologic oncologist and an assistant professor in the Department of Obstetrics and Gynecology at The Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of rucaparib (Rubraca)

FDA Approves Maintenance Rucaparib for Ovarian Cancer

April 6th 2018

The FDA has approved rucaparib for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Dr. Secord on Determining the Management Strategy for Ovarian Cancer

April 6th 2018

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses determining the management strategy for patients with ovarian cancer.

PARP Inhibitors Continue to Impress in Ovarian Cancer

April 5th 2018

Michael Birrer, MD, PhD, discusses the effect that PARP inhibitors have had on the treatment of ovarian cancer, and the potential for combinations with these agents.

Dr. Mirza on the Impact of PARP Inhibitors in Ovarian Cancer

April 2nd 2018

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses the impact of PARP inhibitors in ovarian cancer.

Dr. Birrer on PARP Inhibitors in Ovarian Cancer

March 29th 2018

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Frontline Pembrolizumab Plus Chemo Shows Promise in Ovarian Cancer

March 28th 2018

First-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab, followed by pembrolizumab maintenance, appeared feasible and safe for patients with advanced ovarian cancer, preliminary data from a small clinical trial suggested.

Similar Efficacy Across PARP Inhibitors in Ovarian Cancer, But Safety Analysis Favors Olaparib

March 28th 2018

Currently approved PARP inhibitors have demonstrated similar efficacy in the setting of maintenance therapy for patients with ovarian cancer but differ with respect to the type and frequency of grade 3/4 adverse events, results of a network meta-analysis suggested.

Olaparib/Durvalumab Combo Active in Relapsed Ovarian Cancer

March 27th 2018

Combination therapy with the PARP inhibitor olaparib and the PD-L1 inhibitor durvalumab induced objective responses in more than 70% of patients with relapsed, platinum-sensitive, BRCA-mutated ovarian cancer.